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Abstract: The roles of chemokine C-X-C motif ligand 12 
(CXCL12) and its receptor chemokine C-X-C motif recep-
tor 4 (CXCR4) reveal this chemokine axis as an emerging 
neuromodulator in the nervous system. In the peripheral 
and central nervous systems, both CXCL12 and CXCR4 
are expressed in various kinds of nociceptive structures, 
and CXCL12/CXCR4 axis possesses pronociceptive prop-
erty. Recent studies have demonstrated its critical roles in 
the development and maintenance of pathological pain, 
and both neuronal and glial mechanisms are involved 
in this CXCL12/CXCR4 axis-mediated pain processing. In 
this review, we summarize the recent development of the 
roles and mechanisms of CXCL12/CXCR4 axis in the patho-
genesis of chronic pain by sciatic nerve injury, human 
immunodeficiency virus-associated sensory neuropathy, 
diabetic neuropathy, spinal cord injury, bone cancer, opi-
oid tolerance, or opioid-induced hyperalgesia. The poten-
tial targeting of CXCL12/CXCR4 axis as an effective and 
broad-spectrum pharmacological approach for chronic 
pain therapy was also discussed.
Keywords: CXCL12; CXCR4; neuromodulator; pathological 
pain.
Introduction
Pathological pain is chronic pain lasting for more than 
3 months clinically, and it is divided into three categories 
(neuropathic pain, inflammatory pain, and cancer pain) 
according to pathophysiology (Kuner, 2010). Damage by 
an injury or a disease produces inflammatory molecules 
that alter the property of primary sensory nerve and dorsal 
root ganglion (DRG). As a consequence of peripheral sen-
sitization, the perception and conduction of pain signals 
become abnormal in the peripheral nerve system (PNS). 
These excitatory signals then change neural plasticity in 
the spinal cord and the higher center in the central nerve 
system (CNS). Accordingly, central sensitization is estab-
lished via various mechanisms and contributes to the gen-
eration and maintenance of chronic pain (Basbaum et al., 
2009; Latremoliere and Woolf, 2009).
Chemokine is a small and secreted protein with the 
property of leukocyte chemoattractant. On the basis of 
their molecular structure, chemokines are divided into 
four subfamilies, including C-C, C-X-C, X-C, and C-X3-C 
(Zlotnik and Yoshie, 2000). Chemokines exert their func-
tion by binding to chemokine receptors that belong to the 
G-protein-coupled receptor (GPCR) family (Allen et  al., 
2007). In the nervous system, chemokine signaling modu-
lates neurotransmission and neuronal-glial cross-talk 
(Rostene et al., 2011). Recently, a growing body of preclini-
cal studies has suggested that chemokine axis functions 
as an important modulator in chronic pain processing. 
Chemokine C-X3-C motif ligand 1/chemokine C-X3-C motif 
receptor 1 (CX3CL1/CX3CR1) and chemokine C-C motif 
ligand 2/chemokine C-C motif receptor 2 (CCL2/CCR2) are 
two well-studied chemokine axes in pain research, and 
they modulate the peripheral and central processing of 
pathological pain via multiple mechanisms (White et al., 
2007; Thacker et al., 2009; Van Steenwinckel et al., 2011, 
2015; Li et al., 2015).
CXCL12 (also called stromal cell-derived factor 1, SDF-1) 
belongs to the C-X-C subfamily of chemokine and exerts 
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its function by binding to CXCR4. Chemokine C-X-C motif 
receptor 7 (CXCR7) is newly considered another receptor 
of CXCL12 (Levoye et al., 2009), but to date, there is no evi-
dence of the involvement of CXCR7 in pain processing. The 
pair of CXCL12 and CXCR4 is expressed in the PNS and CNS 
in both constitutive and inducible manners. The distribu-
tion of CXCL12/CXCR4 axis has been reported nearly in all 
cell types in the nervous system, including neuron, astro-
cyte, and microglia (Li and Ransohoff, 2008). As CXCR4 is 
the member of GPCR family, the CXCL12/CXCR4 axis was 
found to be associated with a series of downstream sign-
aling pathways such as phosphatidylinositol 3-kinase, 
nuclear factor kappa light-chain-enhancer of activated 
B cells (NF-κB), nuclear factor of activated T cells, mito-
gen-activated protein kinases (MAPKs) (like extracellular 
signal-regulated kinases [ERKs], c-Jun N-terminal kinases 
[JNKs], and p38), and signal transducers and activa-
tors of transcription pathways in the nervous system (Li 
and  Ransohoff, 2008). Not only does CXCL12/CXCR4 axis 
modulate the neuromodulation, neuroprotection, and 
neuronal-glial interaction in normal conditions, it is also 
involved in the neurological disorder caused by human 
immunodeficiency virus (HIV) infection, tumor, stroke, 
and multiple sclerosis (Li and Ransohoff, 2008). In the 
last few years, an increasing number of pain research in 
CXCL12/CXCR4 axis have shown that it is an emerging neu-
romodulator in pathological pain (Bhangoo et al., 2009; 
Dubovy et  al., 2010; Luo et  al., 2014; Shen et  al., 2014). 
Thus, in this article, the evidence for the involvement of 
CXCL12/CXCR4 axis in pathological pain is reviewed.
CXCL12/CXCR4 axis and nociception
Distribution on nociceptive structures
CXCL12/CXCR4 axis is widely distributed on nociceptive 
structures in the PNS and CNS, which implicates its con-
tribution to pain signal transduction. In the PNS, CXCL12/
CXCR4 axis was found at the peripheral terminal of the 
primary sensory fiber in the glabrous skin (Reaux-Le 
Goazigo et al., 2012). In the sciatic nerve, it was reported 
that CXCL12/CXCR4 axis was colocalized with calcitonin 
gene-related peptide (CGRP)-positive and -negative axonal 
nerve fiber (Reaux-Le Goazigo et  al., 2012). CXCR4 was 
also expressed in Schwann cells in the sciatic nerve (Kury 
et  al., 2002). In DRG, CXCL12 and CXCR4 shared similar 
expression patterns and were predominantly localized 
in the small- and medium-diameter neurons. Moreover, 
double immunolabeling work showed that CXCL12/CXCR4 
axis was distributed in DRG neurons with vanilloid recep-
tor 1, CGRP or isolectin-B4 (IB4)-containing subpopula-
tion and some cells without these immunoreactivity (Oh 
et al., 2001; Reaux-Le Goazigo et al., 2012). In the spinal 
cord, the expression of this chemokine axis was restricted 
mainly at the central terminal of primary sensory fiber 
in the superficial laminae I–III of the dorsal spinal cord 
and colocalized with CGRP-containing neuron (Reaux-Le 
Goazigo et al., 2012).
Although CXCL12/CXCR4 axis is distributed in the 
spinal cord, there are some conflicts on the results of the 
cellular localization of CXCL12 and CXCR4. Shen et  al. 
(2014) reported that CXCL12 was expressed predominantly 
in astrocyte, while CXCR4 was found in spinal neuron 
and microglia with weak immunoreactivity. Reaux-Le 
Goazigo et al. (2012) found that CXCL12 and CXCR4 were 
expressed mainly in the spinal neurons and to a lesser 
extent in the spinal microglia and astrocyte. Using immu-
noelectron microscopy (Reaux-Le Goazigo et al., 2012), it 
was found that CXCL12 and CXCR4 were detected in neu-
ronal organelles including the Golgi apparatus, rough 
endoplasmic reticulum, and the structures at the pre- and 
post- synapse. Moreover, this study demonstrated that the 
primary neuron may release CXCL12/CXCR4 axis-contain-
ing synaptic vesicles from its central terminal to spinal 
dorsal horn.
Pronociceptive property
Further direct evidence for the pronociceptive property of 
CXCL12/CXCR4 axis in nociception comes from pharma-
cological studies. CXCL12 (recombinant CXCL12, same as 
below) or gp120 (HIV-derived agonist of CXCR4) lowered 
the threshold for action potential generation in vitro and 
gp120 stimulated substance P release from cultured neo-
natal DRG neurons (Oh et  al., 2001). Then, an animal 
behavioral test showed that intradermal injection of 
CXCL12 or gp120 caused mechanical allodynia in hind 
paw for hours. These results indicated that CXCL12/CXCR4 
axis is potentially involved in pain signaling. Periph-
eral cellular and molecular mechanisms for CXCL12/
CXCR4 axis-mediated nociceptive processing are further 
delineated in Figure 1. CXCL12/CXCR4 axis can sensitize 
DRG neuron via many pathways, like Src family-kinases 
(SFKs) and intracellular calcium density [Ca2+]i. The incu-
bation of CXCL12 increased the phosphorylation level of 
SFKs in DRG in small- to medium-sized sensory neurons 
in vivo, which was reversed by the coadministration of 
CXCR4 antagonist (Rivat et  al., 2014). Moreover, CXCL12 
and gp120 increased [Ca2+]i in single DRG neuron, but not 
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fibroblasts, in vitro, which was isolated from normal rats 
(Oh et al., 2001). CXCL12 increased the phosphorylation of 
SFKs in satellite glia in vivo (Rivat et al., 2014) and [Ca2+]i in 
Schwann cells in vitro (Kury et al., 2003), which might ini-
tiate pain-related cellular events. Glial cells, like Schwann 
cell and satellite glia, can thus be involved in the periph-
eral nociceptive property of CXCL12/CXCR4 axis.
CXCL12/CXCR4 chemokine axis also exhibits pro-
nociceptive property in the CNS. In intact animals, a 
single intrathecal injection of CXCL12 produced tran-
sient mechanical allodynia, and such allodynia was 
reversed by pretreatment of CXCR4 neutralizing anti-
body (12G5) (Reaux-Le Goazigo et  al., 2012) or CXCR4 
antagonist (AMD3100) intrathecally (Hu et  al., 2015). 
Central mechanisms for CXCL12/CXCR4 in chronic pain 
are also delineated in Figure 2. In a bone cancer pain 
model, the intrathecal administration of AMD3100 
attenuated mechanical allodynia and thermal hyper-
algesia and decreased spinal levels of c-fos (biomarker 
of neural activity), glial fibrillary acidic protein (GFAP; 
biomarker of astrocyte activation), and ionized calcium-
binding adapter molecule 1 (IBA1; biomarker of microglia 
Figure 1: Cellular and molecular mechanisms for CXCL12/CXCR4 
axis in peripheral nociception.
Cell-type biomarkers: GS, glutamine synthetase; GFAP, glial fibril-
lary acidic protein; NeuN, neuronal nuclei; CGRP, calcitonin gene-
related peptide; TRPV1, transient receptor potential cation channel 
subfamily V member 1; SP, substance P; VR1, vanilloid receptor 1; 
MASH2, mammalian achaete scute homolog 2. Pain pathway: SFKs, 
Src family-kinases.
Figure 2: Cellular and molecular mechanisms for CXCL12/CXCR4 
axis in central nociception.
Cell-type biomarkers: GFAP, glial fibrillary acidic protein; NeuN, 
neuronal nuclei; CGRP, calcitonin gene-related peptide; IBA1, 
ionized calcium-binding adapter molecule 1. Pain pathways: SFKs, 
Src family-kinases; MAPK, mitogen-activated protein kinases; 
ERK, extracellular signal-regulated kinases; JNK, c-Jun N-terminal 
kinases.
activation) (Shen et  al., 2014), indicating that neuronal, 
astrocytic, and microglial mechanisms can contribute to 
the role of CXCL12/CXCR4 axis in central pain process-
ing. Multiple molecular pain pathways might account 
for the central pronociceptive property of CXCL12/CXCR4 
axis. In normal rats, the intrathecal injection of CXCL12 
increased the phosphorylation of ERK, JNK, and p38 
pathways in the spinal dorsal horn, and such activation 
was reversed by the pretreatment of AMD3100 (Hu et al., 
2015). Central MAPK pathways are essential for the devel-
opment and maintenance of various types of pathological 
pain in a cell type-specific manner. For example, in the 
spinal cord under pathological pain conditions, ERK was 
activated in neuron, astrocyte, and microglia; JNK was 
activated in astrocyte; and p38 was activated in microglia 
(Ji et  al., 2009). Thus CXCL12/CXCR4 might orchestrate 
pain-related cellular activities in the spinal cord by modu-
lating the activation of MAPK pathways. Moreover, SFKs 
pathway can be involved in the central role of CXCL12/
CXCR4 axis in pain. The intrathecal injection of CXCL12 
increased phosphorylation of SFKs in microglia and some 
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scattered second-order neuron, but not astrocyte, in the 
lumber spinal cord of normal rats (Rivat et al., 2014).
CXCL12/CXCR4 axis and 
 pathological pain
Different events, which occur in the PNS and CNS, may 
account for a unique set of neurochemical and cellular 
changes in different types of chronic pain. For example, 
the pattern of spinal glial activation differs under various 
pathological pain conditions (Watkins and Maier, 2002; 
Cao and Zhang, 2008). As CXCL12/CXCR4 axis contrib-
utes to the neuroinflammation and the neuronal-glial 
interaction (Li and Ransohoff, 2008; Grace et  al., 2014), 
it is speculated that this chemokine axis may participate 
in the processing of different types of pathological pain. 
The involvement of CXCL12/CXCR4 axis in the processing 
of pathological pain is overviewed and elaborated in the 
following sections.
CXCL12/CXCR4 axis and neuropathic pain
Neuropathic pain is caused by a lesion or disease on the 
peripheral or central somatosensory nervous system and 
characterized by spontaneous ongoing or short pain and 
amplified pain response after nonnoxious or noxious 
stimuli (Baron et al., 2010). As CXCL12/CXCR4 axis plays 
essential roles in the biological response to nerve injury 
(Ji et  al., 2004) and in neuromodulation (Guyon and 
Nahon, 2007; Rostene et al., 2007) in the nervous system, 
it is highly possible that this chemokine pair would be 
involved in the pain processing following neuropathy.
CXCL12/CXCR4 axis and sciatic nerve injury
Animal models of sciatic nerve injury are widely used in 
studies of peripheral neuropathic pain (Jaggi et al., 2011), 
especially in CXCL12/CXCR4-related research. The involve-
ment of CXCL12/CXCR4 axis in sciatic neuropathy was 
first found in a rat model of peripheral neuropathic pain, 
in which lysophosphatidylcholine (LPC) was applied into 
the gastrocnemius muscle to cause mechanical allodynia 
(Bhangoo et  al., 2007a). In this model, immunostaining 
work showed that pain hypersensitivity was associated 
with the increased number of DRG neurons expressing 
CXCR4, while CXCL12 expression pattern was not affected. 
By assessing [Ca2+]i in DRG cells acutely isolated from 
LPC-treated rats in vitro, the number of DRG cells respond-
ing to CXCL12 increased following PLC administration. 
In another study, sciatic nerve injury induced by LPC 
increased the frequency of micturition and caused visceral 
pain hypersensitivity (Foster et al., 2011). It was found that 
CXCL12 increased [Ca2+]i in somatic- and bladder-associated 
DRG neurons that were isolated from these PLC-treated 
animals. These findings implicate that CXCL12/CXCR4 axis 
might contribute to the pathogenesis of these complications 
of peripheral neuropathy. Previously, it was found that 
unilateral nerve injury excited neurons, activated satellite 
glia, and initiated macrophage invasion at both ipsilateral 
and contralateral DRG (Dubový et al., 2006, 2007), but the 
mechanisms underlying these phenomena remain unclear. 
Recently, it was shown that chronic constriction injury 
(CCI) operation induced chronic pain, which was associ-
ated with the increased expression of CXCR4 in neuron and 
satellite glia in bilateral lumbar and cervical DRG (Dubovy 
et al., 2010). It was also shown that macrophages exhibit-
ing CXCL12 were recruited to the lumbar DRG following CCI. 
Additionally, intraperitoneal AMD3100 reversed thermal 
hyperalgesia induced by CCI. Therefore, these results impli-
cate that CXCL12/CXCR4 axis may modulate the responses 
of bilateral DRG to unilateral nerve injury.
In a partial sciatic nerve ligation (pSNL) model, we 
first reported the central roles of CXCL12/CXCR4 axis in 
neuropathic pain processing (Luo et al., 2014). Our study 
showed that a single intrathecal injection of AMD3100 
attenuated established hyperalgesia by pSNL in a dose-
dependent manner. Using real-time polymerase chain 
reaction (PCR) and Western blotting, it was found that 
such intrathecal AMD3100 injection downregulated the 
activation of glia-related pain pathways, like MAPKs (JNK, 
p38) and NF-κB (p65), and modulated the spinal expres-
sion of pain molecules, like substance P and intracellu-
lar adhesive molecule-1 (proinflammatory molecule and 
indicator of the permeability of the blood-brain barrier; 
Lee and Benveniste, 1999). These findings further indicate 
that besides the neurons, multiple downstream mecha-
nisms associated with glia-related pain pathways were 
involved in CXCL12/CXCR4 axis-mediated central process-
ing of neuropathic pain.
CXCL12/CXCR4 axis and HIV-associated sensory 
neuropathy
HIV-associated neuropathic pain occurs in one third of 
AIDS patients. Although the pathophysiology of this pain 
disorder remains largely unclear, the mechanisms involv-
ing gp120, immune pathogenic factors, and nucleoside 
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reverse transcriptase inhibitors (NRTIs) have been pro-
posed (Verma et al., 2005). CXCR4 is a coreceptor of HIV-1 
gp120 and plays vital roles in the invasion of virus to host 
cells (Alkhatib, 2009). The intradermal injection of gp120 
or CXCL12 in rat hind paw caused transient allodynia (Oh 
et  al., 2001). Therefore, as a pronociceptive component, 
CXCL12/CXCR4 axis would be potentially a therapeutic 
target for HIV-associated sensory neuropathy. Intraperi-
toneal injection of 2′,3′-dideoxycytidine (ddC; an NRTI) 
caused sciatic nerve injury and mechanical allodynia and 
increased mRNA level of CXCL12 and CXCR4 in DRG non-
neuronal cells in vivo (Bhangoo et al., 2007b). In cultured 
DRG isolated from rats treated with ddC or vehicle, ddC 
treatment increased the number of cells responding to 
CXCL12 by monitoring [Ca2+]i, indicating functional CXCR4 
was increased in DRG following NRTI treatment. More-
over, the intraperitoneal administration of AMD3100 tran-
siently reversed established mechanical allodynia by ddC 
treatment. These results are the first to report the involve-
ment of CXCL12/CXCR4 axis in DRG processing of NRTI-
induced neuropathy. Perineural administration of gp120 
caused sciatic nerve injury and persistent pain in rat hind 
paw (Zheng et  al., 2014). Herpes simplex virus vectors 
expressing anti-inflammatory cytokine, interleukin 10 
(IL-10), was constructed and injected into ipsilateral hind 
paw of gp120-treated rats, which reversed the established 
mechanical allodynia. In this gp120-induced neuro-
pathic pain model, overexpressed exogenous IL-10 down-
regulated the phosphorylation of p38 and decreased the 
protein levels of tumor necrosis factor-α (TNF-α), CXCL12, 
and CXCR4 at both DRG and spinal dorsal horn by Western 
blotting. This study demonstrated that both central and 
peripheral CXCL12/CXCR4 axis might contribute to pain 
processing of HIV-associated sensory neuropathy. In a 
model combining the application of perineural gp120 and 
intraperitoneal ddC, it was shown that such dual-drug 
treatment increased CXCL12 signaling in sensory neuron 
in DRG and intraperitoneal AMD3100 reversed mechani-
cal allodynia induced by gp120 and ddC, but not hyperal-
gesia only induced by gp120 (Bhangoo et al., 2009). This 
research uncovers that gp120, but not ddC, may induce 
hyperalgesia via a CXCR4-independent manner.
CXCL12/CXCR4 axis and diabetic neuropathy
Diabetic neuropathy occurs in one quarter of diabetic 
patients, and its mechanisms remain largely unknown 
(Albers and Pop-Busui, 2014). In an in vivo work, two 
animal models of type II diabetes (mice treated with high-
fat diet [HFD] and transgenic mice without leptin receptor) 
were used to study the peripheral roles of CXCL12/CXCR4 
axis in painful diabetic neuropathy ( Menichella et  al., 
2014). In two models of type II diabetes, mice showed 
mechanical allodynia, and the intraperitoneal adminis-
tration of AMD3100 reversed such neuropathic pain for 
hours. CXCL12 increased [Ca2+]i in DRG sensory neurons 
in vivo, which were acutely isolated from mice with HFD-
induced diabetes. The infiltration of CXCR4-expressing 
CD3 positive T cells to DRG was also shown in this study. 
All those results suggest the potential roles of CXCL12/
CXCR4 axis-targeted therapy in the management of 
painful diabetic neuropathy.
CXCL12/CXCR4 axis and spinal cord injury
Neuropathic pain is not uncommon after spinal cord 
injury, and its pathology and therapeutic strategy are 
unclear (Finnerup, 2013). As CXCL12/CXCR4 axis orches-
trates cellular events involved in the recovery process 
following the spinal cord injury (Tysseling et  al., 2011; 
Jaerve et al., 2012), this chemokine axis might contribute 
to the pathophysiology of spinal cord neuropathy. The 
spinal expression and distribution of CXCL12/CXCR4 were 
reported in a rat model of spinal cord injury (Knerlich-
Lukoschus et al., 2011). Spinal cord contusion increased 
the expression of CXCL12/CXCR4 axis in the dorsal horn 
and dorsal column. Double immunolabeling work showed 
that spinal CXCL12/CXCR4 axis was expressed on neurons, 
astrocytes, and microglia/macrophages in rat with spinal 
cord injury. This is the first study that showed the associa-
tion of CXCL12/CXCR4 axis with central neuropathic pain, 
which needs to be warranted by further pharmacological 
and behavioral evidence.
CXCL12/CXCR4 axis and cancer pain
Various types of factors such as prostaglandins, TNF-α, 
and endothelin secreted by tumor and/or the extension 
of tumor tissue sensitize or excite the primary afferent 
sensory neuron in DRG. Persistent noxious stimuli from 
tumor tissue also sensitize sensory structures in the spinal 
cord and the higher centers in the brain (Mantyh et  al., 
2002). CXCL12/CXCR4 axis plays important roles in many 
aspects of the cancer biology, including angiogenesis and 
metastasis (Teicher and Fricker, 2010). Current research 
focuses on the central role of CXCL12/CXCR4 axis in pain 
processing following oncogenesis. In a rat model of bone 
cancer pain, astrocytic mechanisms for the involvement of 
CXCL12/CXCR4 axis in cancer pain processing were found 
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(Shen et al., 2014). In this study, the tumor cell implanta-
tion (TCI) into rat tibial cavity produced persistent cancer 
pain and upregulated the expression of CXCL12 at DRG 
and spinal cord in vivo. As CXCL12 was expressed mainly 
in spinal astrocytes following TCI, the intrathecal admin-
istration of astrocytic activation inhibitor (fluorocitrate) 
or selective JNK inhibitor (SP600125) blocked such TCI-
induced increase in spinal CXCL12 expression. TCI trig-
gered the increase in CXCR4 expression in spinal cord 
following the surgery, which was colocalized mainly with 
NeuN (biomarker of neuron) and GFAP and a small amount 
with IBA1. This study also reported that the intrathe-
cal injection of CXCL12 neutralizing antibody or CXCR4 
antagonist (AMD3100) attenuated the initiation and main-
tenance of cancer pain. Intrathecal AMD3100 also sup-
pressed the activation of neuron (c-Fos), astrocyte (GFAP), 
and microglia (IBA1) induced by TCI treatment, indicating 
that CXCL12/CXCR4 axis may contribute to cancer pain pro-
cessing via neuronal and glial mechanisms in the CNS. In a 
subsequent research, intrathecal injection of CXCL12 neu-
tralizing antibody attenuated cancer pain and decreased 
the level of IBA1 following TCI treatment (Liu et al., 2014). 
The results suggested that microglia might also be involved 
in CXCL12/CXCR4-mediated cancer pain processing in the 
CNS. Furthermore, in the same model, it was found that TCI 
treatment increased the phosphorylation of MAPK path-
ways and the production of proinflammatory cytokines (IL-
1β, IL-6, and TNF-α) in the lumbar spinal cord (Hu et al., 
2015). The blockade of CXCL12/CXCR4 axis by AMD3100 
or CXCL12 neutralizing antibody or MAPK pathways (by 
ERK inhibitor [U0126], JNK inhibitor [SP600125], or p38 
inhibitor [SB503580]) reversed persistent pain and down-
regulated the production of these cytokines in a rat bone 
cancer model. This study indicates that spinal MAPK path-
ways might be associated with CXCL12/CXCR4-mediated 
neuroinflammation under cancer condition.
CXCL12/CXCR4 axis and opioid tolerance 
and hyperalgesia
Although opioid therapy is accepted as an effective treat-
ment for chronic pain, the efficacy decreases with time due 
to opioid tolerance or opioid-induced hyperalgesia (OIH) 
(Chan et al., 2011). Recently, the crosstalk between opioid 
and chemokine receptor provides novel concepts in reduc-
ing the complications of clinical opioid use ( Parsadaniantz 
et al., 2015). As a member of the GPCR family, CXCR4 het-
erodimerizes with opioid receptor (like mu-opioid receptor 
[MOR] or delta-opioid receptor [DOR]) on cell membrane 
and modulates opioid-mediated activities under various 
pathological conditions, such as ischemia-induced myo-
cardial infarction and HIV invasion (Kramp et  al., 2011). 
Therefore, CXCL12/CXCR4 axis is proposed to function in 
the pathology of opioid tolerance and OIH.
CXCL12/CXCR4 axis and opioid tolerance
CXCR4 was coexpressed with MOR in various areas in 
rat brain, including the hippocampus, cingulate cortex, 
and periaqueductal grey (PAG) (Heinisch et al., 2011). In 
uninjured animals, double immunolabeling work showed 
that CXCR4 was distributed on cells expressing DOR and 
MOR at lumbar DRG and spinal dorsal horn, implicating 
that CXCL12/CXCR4 axis might influence opioid recep-
tor activity (Rivat et al., 2014). Opioid-induced analgesia 
by [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO), an 
agonist of MOR, in rats was abolished by the adminis-
tration of CXCL12 in PAG (Szabo et al., 2002). These find-
ings demonstrated that CXCL12/CXCR4 axis might play a 
central role in opioid signaling in the CNS. Using electro-
physiological tools in vitro, it was found that exogenous 
CXCL12 blocked the response of PAG neuron to morphine-
induced hyperpolarization and reduction of input resist-
ance (Heinisch et al., 2011). This study further suggests the 
involvement of CXCL12/CXCR4 axis in opioid-mediated 
intracellular events in neurons. PAG injection of DAMGO 
or [D-Pen(2), D-Pen(5)]-enkehphalin (DPDPE) (agonist of 
DOR) increased the latency to flick the tail in cold water in 
rats, and such antinociceptive effect was blocked by pre-
treated or cotreated of CXCL12 in PAG (Chen et al., 2007). 
This work indicates that CXCL12/CXCR4 axis might modu-
late opioid-induced analgesia by interacting with DOR 
and MOR rapidly in PAG. PAG injection of buprenorphine, 
an artificial derivative of thebaine and opioid-like peptide, 
increased the latency to flick the tail in cold water in rats, 
and such analgesic effect was not affected by coadminis-
trated CXCL12 (Benamar et al., 2011). Then, PAG injection 
of buprenorphine and methadone caused an analgesic 
effect in rats in a hot plate test, and such analgesic effect 
of methadone, but not buprenorphine, was blocked 
by cotreated gp120 (Palma et  al., 2011). Findings from 
these two studies implicate that buprenorphine could be 
applied to patients who suffer opioid tolerance by endog-
enous CXCL12/CXCR4 axis in the CNS.
In cultured DRG neuron, it was found that an SFK 
inhibitor (PP2) increased the constitutive activity of MOR 
and downregulated the recycling of MOR (Walwyn et al., 
2007). In engineered Chinese hamster ovary cells stably 
expressing DOR, DPDPE promoted intracellular activities 
(like the recruitment and dephosphorylation of β-arrestin) 
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associated with DOR in vitro, and such effect by DPDPE 
was suppressed by the coadministration of PP2 (Hong 
et al., 2009). The results from those studies suggest that 
SFKs might be involved in the pathology of opioid toler-
ance by regulating MOR and DOR activities. Recently, how 
CXCL12/CXCR4 axis caused a loss in morphine analgesia 
via SFK mechanism was studied (Rivat et al., 2014). This 
study showed that CXCL12 activated SFK pathway (phos-
phorylation) on primary DRG neuron in vitro, and such 
effects were blocked by the coincubation of an CXCR4 
antagonist (IT1t). it was also shown that the intrathecal 
injection of CXCL12 increased the phosphorylation of SFKs 
in a subpopulation of cells containing MOR and DOR at 
the spinal dorsal horn. Morphine was applied subcutane-
ously and caused an analgesic effect in rats by increasing 
painful threshold in paw pressure vocalization test. The 
intrathecal administration of CXCL12 blocked such mor-
phine-induced analgesic effect, while intrathecal IT1t pro-
longed the period of such analgesic effect. Moreover, the 
intrathecal treatment of PP2 blocked the effect by intrath-
ecal CXCL12 on morphine-induced analgesia, and such 
findings were consistent with their immunohistological 
evidence at the spinal dorsal horn. Their work implicates 
that endogenous CXCL12/CXCR4 axis may be a therapeutic 
target to treat opioid tolerance (Parsadaniantz et al., 2015).
CXCL12/CXCR4 axis and OIH
It has been a long-term concern in anesthesiology that 
OIH limits the clinical efficacy of opioid therapy in both 
clinical and laboratory research (Angst and Clark, 2006; 
Chu et al., 2008). Recently, evidence from an in vivo study 
directly proves that CXCL12/CXCR4 axis was essential to 
the pathology of OIH (Wilson et al., 2011). In this study, it 
was found that repeated intraperitoneal injection of mor-
phine induced tactile hyperalgesia, which was attenuated 
by intraperitoneal administration of AMD3100 in rats. 
Moreover, repeated intraperitoneal injection of morphine 
caused an increase in CXCL12 expression and a decrease in 
CXCR4 expression in DRG in vivo. Interestingly, intraperito-
neal administration of AMD3100 reversed the decrease in 
CXCR4 expression in DRG in these morphine-treated rats.
Prospect
Neural plasticity-targeted pain management does not 
attain the expected purpose for some side effect (like 
addiction and tolerance) (Dworkin et  al., 2003). Given 
the contribution of chemokine signaling to neuromodula-
tion, chemokine axis-targeted therapy is taken as a novel 
method for pathological pain management (Gao and Ji, 
2010; Ji et  al., 2014). Currently, CXCL12/CXCR4 axis has 
been proven to play an essential role in the pathogenesis 
of neuropathic pain, cancer pain, and opioid tolerance 
and hyperalgesia, as shown in Figure 3 for its cellular 
and molecular mechanisms in pain processing in the PNS 
and/or CNS under these pathological conditions. Future 
work will explore the peripheral and central roles of 
CXCL12/CXCR4 axis in pain processing under pathological 
conditions, in which the function of this chemokine axis 
remains still unknown. Output from these studies will help 
to evaluate whether CXCL12/CXCR4 axis could be an effec-
tive and board-spectrum target for chronic pain therapy. 
The interaction between chemokine and opioid system 
has been considered an emerging target to improve the 
efficacy of opioid therapy (Parsadaniantz et al., 2015). As 
CXCL12/CXCR4 axis is central for the pathology of opioid 
tolerance (Rivat et al., 2014) and OIH (Wilson et al., 2011), 
the blockade of CXCL12/CXCR4 axis could be an adjunc-
tive strategy for opioid therapy. Therefore, preclinical and/
or clinical studies on this topic are necessary to evaluate 
such possibility. Numerous drugs have been designed 
for blocking chemokine signaling; however, the efficacy 
of these chemokine receptor antagonists is poor in pre-
clinical and clinical studies (Pease and Horuk, 2009a,b). 
Therefore, the improvement of efficacy of CXCL12/CXCR4 
axis-targeted therapy should be the major concern for 
its future application. Even though some reasons for the 
poor response have been proposed, like pharmacokinetic 
properties, species selectivity, and drug metabolism (Gao 
and Ji, 2010), an effective solution to this problem has 
not been reported. In our previous study, it was found 
that the antiallodynia effects of AMD3100 by injecting 
centrally lasted for 3–4 days (Luo et al., 2014), but such 
effects by injecting peripherally only lasted for hours 
(Bhangoo et al., 2007b, 2009; Dubovy et al., 2010; Wilson 
et al., 2011). Therefore, we hypothesize that the efficacy of 
CXCL12/CXCR4 axis-related therapy may depend on how 
it is delivered, and more evidence is needed to prove this.
Conclusion
A growing body of preclinical evidence suggests a wide 
involvement of CXCL12/CXCR4 axis in pathological pain. 
This chemokine axis modulates peripheral sensitization 
through neuronal and glial mechanisms. The CXCL12/
CXCR4 axis also contributes to central sensitization by 
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mechanisms such as neuroinflammation and neuronal-
glial interaction. Thus, all these findings inspire coming 
studies to integrate CXCL12/CXCR4 axis into our current 
pain knowledge. The potential of CXCL12/CXCR4-targeted 
therapy in future management of pathological pain 
requests further extensive exploration.
Acknowledgments: This research is supported by the 
department fund, Department of Anaesthesiology, The 
University of Hong Kong, Hong Kong SAR, China.
Conflict of interest disclosure: The authors have no con-
flict of interest to declare.
References
Albers, J.W. and Pop-Busui, R. (2014). Diabetic neuropathy: mecha-
nisms, emerging treatments, and subtypes. Curr. Neurol. 
Neurosci. Rep. 14, 11.
Alkhatib, G. (2009). The biology of CCR5 and CXCR4. Curr. Opin. HIV 
AIDS 4, 96–103.
Allen, S.J., Crown, S.E., and Handel, T.M. (2007). Chemokine: 
receptor structure, interactions, and antagonism. Ann. Rev. 
Immunol. 25, 787–820.
Angst, M.S. and Clark, J.D. (2006). Opioid-induced hyperalgesia – a 
qualitative systematic review. Anesthesiology 104, 570–587.
Baron, R., Binder, A., and Wasner, G. (2010). Neuropathic pain: diag-
nosis, pathophysiological mechanisms, and treatment. Lancet 
Neurol. 9, 807–819.
Figure 3: Cellular and molecular mechanisms for the role of CXCL12/CXCR4 axis in the processing of neuropathic pain, cancer pain, and 
opioid tolerance and hyperalgesia.
Cell-type biomarkers: GS, glutamine synthetase; ED1, also called cluster of differentiation (CD) 68; IB4, isolectin B4; TRPV1, transient recep-
tor potential cation channel subfamily V member 1; CD3, cluster of differentiation 3; GFAP, glial fibrillary acidic protein; NF200, neurofila-
ment-200; SP, substance P; CGRP, calcitonin gene-related peptide; NeuN, neuronal nuclei; IBA1, ionized calcium-binding adapter molecule 
1. Pain molecules and pathways: JNK, c-Jun N-terminal kinases; ICAM-1, intracellular adhesive molecule-1; TNF-α, tumor necrosis factor α; 
IL-1β, interleukin 1β; SFKs, Src family-kinases; MOR, μ-opioid receptors; DOR, δ-opioid receptor.
Brought to you by | University of Hong Kong Libraries
Authenticated
Download Date | 5/25/16 9:51 AM
X. Luo et al.: CXCL12/CXCR4 axis in pain      91
Basbaum, A.I., Bautista, D.M., Scherrer, G., and Julius, D. (2009). 
Cellular and molecular mechanisms of pain. Cell 139, 267–284.
Benamar, K., Palma, J., Cowan, A., Geller, E.B., and Adler, M.W. 
(2011). Analgesic efficacy of buprenorphine in the presence 
of high levels of SDF-1a/CXCL12 in the brain. Drug Alcohol 
Depend. 114, 246–248.
Bhangoo, S., Ren, D., Miller, R. J., Henry, K.J., Lineswala, J., 
 Hamdouchi, C., Li, B., Monahan, P.E., Chan, D.M., Ripsch, 
M.S., et al. (2007a). Delayed functional expression of neuronal 
chemokine receptors following focal nerve demyelination in 
the rat: a mechanism for the development of chronic sensitiza-
tion of peripheral nociceptors. Mol. Pain 3, 38.
Bhangoo, S.K., Ren, D.J., Miller, R.J., Chan, D.M., Ripsch, M.S., 
Weiss, C., McGinnis, C., and White, F.A. (2007b). CXCR4 
chemokine receptor signaling mediates pain hypersensitiv-
ity in association with antiretroviral toxic neuropathy. Brain 
Behav. Immun. 21, 581–591.
Bhangoo, S.K., Ripsch, M.S., Buchanan, D.J., Miller, R.J., and 
White, F.A. (2009). Increased chemokine signaling in a model 
of HIV1-associated peripheral neuropathy. Mol. Pain 5, 48.
Cao, H. and Zhang, Y.Q. (2008). Spinal glial activation contributes to 
pathological pain states. Neurosci. Biobehav. Rev. 32, 972–983.
Chan, B.K.B., Tam, L.K., Wat, C.Y., Chung, Y.F., Tsui, S.L., and 
Cheung. C.W. (2011). Opioids in chronic non-cancer pain. 
Expert Opin. Pharmacother. 12, 705–720.
Chen, X.H., Geller, E.B., Rogers, T.J., and Adler, M.W. (2007). Rapid 
heterologous desensitization of antinociceptive activity 
between mu or delta opioid receptors and chernokine recep-
tors in rats. Drug Alcohol Depend. 88, 36–41.
Chu, L.F., Angst, M.S., and Clark, D. (2008). Opioid-induced 
hyperalgesia in humans – molecular mechanisms and clinical 
considerations. Clin. J. Pain 24, 479–496.
Dubový, P., Jančálek, R., Klusáková, I., Svíženská, I., and Pejchalová, 
K. (2006). Intra- and extraneuronal changes of immunofluores-
cence staining for TNF- and TNFR1 in the dorsal root ganglia of 
rat peripheral neuropathic pain models. Cell. Mol. Neurobiol. 
26, 1203–1215.
Dubový, P., Tučková, L., Jančálek, R., Svíženská, I., and Klusáková, I. 
(2007). Increased invasion of ED-1 positive macrophages 
in both ipsi- and contralateral dorsal root ganglia following 
 unilateral nerve injuries. Neurosci. Lett. 427, 88–93.
Dubovy, P., Klusakova, I., Svizenska, I., and Brazda, V. (2010). 
Spatio-temporal changes of SDF1 and its CXCR4 receptor in the 
dorsal root ganglia following unilateral sciatic nerve injury as a 
model of neuropathic pain. Histochem. Cell Biol. 133, 323–337.
Dworkin, R.H., Backonja, M., Rowbotham, M.C., Allen, R.R.,  Argoff, 
C.R., Bennett, G.J., Bushnell, M.C., Farrar, J.T., Galer, B.S., 
 Haythornthwaite, J.A., et al. (2003). Advances in neuropathic 
pain – diagnosis, mechanisms, and treatment recommenda-
tions. Arch. Neurol. 60, 1524–1534.
Finnerup, N.B. (2013). Pain in patients with spinal cord injury. Pain 
154, S71–S76.
Foster, R., Jung, J., Farooq, A., McClung, C., Ripsch, M.S., Fitzger-
ald, M.P., and White, F.A. (2011). Sciatic nerve injury induces 
functional pro-nociceptive chemokine receptors in bladder-
associated primary afferent neurons in the rat. Neuroscience 
183, 230–237.
Gao, Y.J. and Ji, R.R. (2010). Chemokines, neuronal-glial interac-
tions, and central processing of neuropathic pain. Pharmacol. 
Ther. 126, 56–68.
Grace, P.M., Hutchinson, M.R., Maier, S.F., and Watkins, L.R. (2014). 
Pathological pain and the neuroimmune interface. Nat. Rev. 
Immunol. 14, 217–231.
Guyon, A. and Nahon, J.L. (2007). Multiple actions of the chemokine 
stromal cell-derived factor-1 alpha on neuronal activity. J. Mol. 
Endocrinol. 38, 365–376.
Heinisch, S., Palma, J., and Kirby, L.G. (2011). Interactions between 
chemokine and mu-opioid receptors: anatomical findings and 
electrophysiological studies in the rat periaqueductal grey. 
Brain Behav. Immun. 25, 360–372.
Hong, M.H., Xu, C., Wang, Y.J., Ji, J.L., Tao, Y.M., Xu, X.J., Chen, J., 
Xie, X., Chi, Z.Q., and Liu, J.G. (2009). Role of Src in ligand-
specific regulation of d-opioid receptor desensitization and 
internalization. J. Neurochem. 108, 102–114.
Hu, X.-M., Liu, Y.-N., Zhang, H.-L., Cao, S.-B., Zhang, T., Chen, L.-P., 
and Shen, W. (2015). CXCL12/CXCR4 chemokine signaling 
in spinal glia induces pain hypersensitivity through MAPKs- 
mediated neuroinflammation in bone cancer rats. J. Neuro-
chem. 132, 452–463.
Jaerve, A., Bosse, F., and Muller, H.W. (2012). SDF-1/CXCL12: its role 
in spinal cord injury. Int. J. Biochem. Cell Biol. 44, 452–456.
Jaggi, A.S., Jain, V., and Singh, N. (2011). Animal models of neuro-
pathic pain. Fundam. Clin. Pharmacol. 25, 1–28.
Ji, J.F., He, B.P., Dheen, S.T., and Tay, S.S.W. (2004). Interactions of 
chemokines and chemokine receptors mediate the migration of 
mesenchymal stem cells to the impaired site in the brain after 
hypoglossal nerve injury. Stem Cells 22, 415–427.
Ji, R.R., Gereau, R.W., Malcangio, M., and Strichartz, G.R. (2009). 
MAP kinase and pain. Brain Res. Rev. 60, 135–148.
Ji, R.R., Xu, Z.Z., and Gao, Y.J. (2014). Emerging targets in neuro-
inflammation-driven chronic pain. Nat. Rev. Drug Discov. 13, 
533–548.
Knerlich-Lukoschus, F., von der Ropp-Brenner, B., Lucius, R., 
 Mehdorn, H.M., and Held-Feindt, J. (2011). Spatiotemporal 
CCR1, CCL3(MIP-1 alpha), CXCR4, CXCL12(SDF-1a) expression 
patterns in a rat spinal cord injury model of posttraumatic 
neuropathic pain. J. Neurosurg. Spine 14, 583–597.
Kramp, B.K., Sarabi, A., Koenen, R.R., and Weber, C. (2011). 
 Heterophilic chemokine receptor interactions in chemokine 
signaling and biology. Exp. Cell Res. 317, 655–663.
Kuner, R. (2010). Central mechanisms of pathological pain. Nat. 
Med. 16, 1258–1266.
Kury, P., Greiner-Petter, R., Cornely, C., Jurgens, T., and Muller, H.W. 
(2002). Mammalian achaete scute homolog 2 is expressed in 
the adult sciatic nerve and regulates the expression of Krox24, 
Mob-1, CXCR4, and p57kip2 in Schwann cells. J. Neurosci. 22, 
7586–7595.
Kury, P., Koller, H., Hamacher, M., Comely, C., Hasse, B., and Muller, 
H.W. (2003). Cyclic AMP and tumor necrosis factor-a regulate 
CXCR4 gene expression in Schwann cells. Mol. Cell. Neurosci. 
24, 1–9.
Latremoliere, A. and Woolf, C.J. (2009). Central sensitization: a 
generator of pain hypersensitivity by central neural plasticity. 
J. Pain 10, 895–926.
Lee, S.J. and Benveniste, E.N. (1999). Adhesion molecule expres-
sion and regulation on cells of the central nervous system. J. 
Neuroimmunol. 98, 77–88.
Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., and Lagane, B. 
(2009). CXCR7 heterodimerizes with CXCR4 and regulates 
CXCL12-mediated G protein signaling. Blood 113, 6085–6093.
Brought to you by | University of Hong Kong Libraries
Authenticated
Download Date | 5/25/16 9:51 AM
92      X. Luo et al.: CXCL12/CXCR4 axis in pain
Li, M.Z. and Ransohoff R.A. (2008). Multiple roles of chemokine 
CXCL12 in the central nervous system: a migration from immu-
nology to neurobiology. Prog. Neurobiol. 84, 116–131.
Li, D., Huang, Z.Z., Ling, Y.Z., Wei, J.Y., Cui, Y., Zhang, X.Z., Zhu, H.Q., 
and Xin, W.J. (2015). Up-regulation of CX3CL1 via nuclear 
factor-kB-dependent histone acetylation is involved in 
paclitaxel-induced peripheral neuropathy. Anesthesiology 
122, 1142–1151.
Liu, Y., Shen, W., Hu, X., Chen, L., Cao, S., and Zhang, T. (2014). Role 
of chemokine CXCL12 in spinal cord in development of bone 
cancer pain in rats: relationship with microglial activation. 
Chin. J. Anesthesiol. 34, 40–42.
Luo, X., Tai, W.L., Sun, L., Qiu, Q., Xia, Z., Chung, S.K., and 
Cheung, C.W. (2014). Central administration of C-X-C 
chemokine receptor type 4 antagonist alleviates the develop-
ment and maintenance of peripheral neuropathic pain in mice. 
PLoS One 9, e104860.
Mantyh, P.W., Clohisy, D.R., Koltzenburg, M., and Hunt, S.P. (2002). 
Molecular mechanisms of cancer pain. Nat. Rev. Cancer 2, 
201–209.
Menichella, D.M., Abdelhak, B., Ren, D., Shum, A., Frietag, C., 
and Miller, R.J. (2014). CXCR4 chemokine receptor signaling 
 mediates pain in diabetic neuropathy. Mol. Pain 10, 13.
Oh, S.B., Tran, P.B., Gillard, S.E., Hurley, R.W., Hammond, D.L., and 
Miller, R.J. (2001). Chemokines and glycoprotein 120 produce 
pain hypersensitivity by directly exciting primary nociceptive 
neurons. J. Neurosci. 21, 5027–5035.
Palma, J., Cowan, A., Geller, E.B., Adler, M.W., and Benamar, K. 
(2011). Differential antinociceptive effects of buprenorphine 
and methadone in the presence of HIV-gp120. Drug Alcohol 
Depend. 118, 497–499.
Parsadaniantz, S.M., Rostene, W., and Goazigo, A.R.L. (2015). 
 Opioid and chemokine receptor crosstalk: a promising target 
for pain therapy? Nat. Rev. Neurosci. 16, 69–78.
Pease, J.E. and Horuk, R. (2009a). Chemokine receptor antagonists: 
part 1. Expert Opin. Ther. Pat. 19, 39–58.
Pease, J.E. and Horuk, R. (2009b). Chemokine receptor antagonists: 
part 2. Expert Opin. Ther. Pat. 19, 199–221.
Reaux-Le Goazigo, A., Rivat, C., Kitabgi, P., Pohl, M., and 
 Parsadaniantz, S.M. (2012). Cellular and subcellular locali-
zation of CXCL12 and CXCR4 in rat nociceptive structures: 
 physiological relevance. Eur. J. Neurosci. 36, 2619–2631.
Rivat, C., Sebaihi, S., Van Steenwinckel, J., Fouquet, S., Kitabgi, P., 
Pohl, M., Parsadaniantz, S.M., and Reaux-Le Goazigo, A. 
(2014). Src family kinases involved in CXCL12-induced loss of 
acute morphine analgesia. Brain Behav. Immun. 38, 38–52.
Rostene, W., Kitabgi, P., and Melik-Parsadaniantz, S. (2007). 
 Opinion – chemokines: a new class of neuromodulator? Nat. 
Rev. Neurosci. 8, 895–904.
Rostene, W., Dansereau, M.A., Godefroy, D., Van Steenwinckel, J., 
Goazigo, A.R.L., Melik-Parsadaniantz, S., Apartis, E., Hunot, S., 
Beaudet, N., and Sarret, P. (2011). Neurochemokines: a menage 
a trois providing new insights on the functions of chemokines 
in the central nervous system. J. Neurochem. 118, 680–694.
Shen, W., Hu, X.M., Liu, Y.N., Han, Y., Chen, L.P., Wang, C.C., and 
Song, C. (2014). CXCL12 in astrocytes contributes to bone 
cancer pain through CXCR4-mediated neuronal sensitization 
and glial activation in rat spinal cord. J. Neuroinflammation 
11, 75.
Szabo, I., Chen, X.H., Xin, L., Adler, M.W., Howard, O.M.Z., 
 Oppenheim, J.J., and Rogers, T.J. (2002). Heterologous 
 desensitization of opioid receptors by chemokines inhibits 
chemotaxis and enhances the perception of pain. Proc. Natl. 
Acad. Sci. USA 99, 10276–10281.
Teicher, B.A. and Fricker, S.P. (2010). CXCL12 (SDF-1)/CXCR4 
 pathway in cancer. Clin. Cancer Res. 16, 2927–2931.
Thacker, M.A., Clark, A.K., Bishop, T., Grist, J., Yip, P.K., Moon, L.D.F, 
Thompson, S.W.N., Marchand, F., and McMahon, S.B. (2009). 
CCL2 is a key mediator of microglia activation in neuropathic 
pain states. Eur. J. Pain 13, 263–272.
Tysseling, V.M., Mithal, D., Sahni, V., Birch, D., Jung, H.S., Miller, 
R.J., and Kessler, J.A. (2011). SDF1 in the dorsal corticospinal 
tract promotes CXCR4+ cell migration after spinal cord injury. 
J. Neuroinflammation 8, 8.
Van Steenwinckel, J., Reaux-Le Goazigo, A., Pommier, B., 
 Mauborgne, A., Dansereau, M.A., Kitabgi, P., Sarret, P., Pohl, 
M., and Parsadaniantz, S.M. (2011). CCL2 released from neu-
ronal synaptic vesicles in the spinal cord is a major mediator 
of local inflammation and pain after peripheral nerve injury. J. 
Neurosci. 31, 5865–5875.
Van Steenwinckel, J., Auvynet, C., Sapienza, A., Goazigo, A.R.L., 
Combadiere, C., and Parsadaniantz, S.M. (2015). Stromal cell-
derived CCL2 drives neuropathic pain states through myeloid 
cell infiltration in injured nerve. Brain Behav. Immun. 45, 
198–210.
Verma, S., Estanislao, L., and Simpson, D. (2005). HIV-associated 
neuropathic pain – epidemiology, pathophysiology and man-
agement. CNS Drugs 19, 325–334.
Walwyn, W., Evans, C.J., and Hales, T.G. (2007). beta-Arrestin2 and 
c-Src regulate the constitutive activity and recycling of mu 
opioid receptors in dorsal root ganglion neurons. J. Neurosci. 
27, 5092–5104.
Watkins, L.R. and Maier, S.F. (2002). Beyond neurons: evidence that 
immune and glial cells contribute to pathological pain states. 
Physiol. Rev. 82, 981–1011.
White, F.A., Jung, H., and Miller, R.J. (2007). Chemokines and the 
pathophysiology of neuropathic pain. Proc. Natl. Acad. Sci. 
USA 104, 20151–20158.
Wilson, N.M., Jung, H.S., Ripsch, M.S., Miller, R.J., and White, F.A. 
(2011). CXCR4 signaling mediates morphine-induced tactile 
hyperalgesia. Brain Behav. Immun. 25, 565–573.
Zheng, W.W., Huang, W., Liu, S., Levitt, R.C., Candiotti, K.A., 
Lubarsky, D.A., and Hao, S.L. (2014). Interleukin 10 mediated 
by herpes simplex virus vectors suppresses neuropathic pain 
induced by human immunodeficiency virus gp120 in rats. 
Anesth. Analg. 119, 693–701.
Zlotnik, A. and Yoshie, O. (2000). Chemokines: a new classification 
system and their role in immunity. Immunity 12, 121–127.
Brought to you by | University of Hong Kong Libraries
Authenticated
Download Date | 5/25/16 9:51 AM
